Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Acorda Therapeutics
So what: European and Canadian regulators shocked Acorda owners by separately recommending against approval of multiple sclerosis drug Ampyra, raising questions about the pill's effectiveness weighed against the potential risks. The decision also damaged marketing partner Biogen Idec
Now what: As an Ampyra user myself, I can attest to the symptom-modifying drug's effectiveness in at least one case. But anecdotal evidence won't do much to sway regulators, and the drug does have well-documented side effects. Acorda may have to go back to the lab again while leaning on American sales, but MS research continues unabated elsewhere – Novartis'
Interested in more info on Acorda Therapeutics? Add it to your watchlist.
Fool contributor Anders Bylund doesn't hold a position in any of the companies discussed here, but he is grateful for his daily dose of Ampyra. Novartis is a Motley Fool Global Gains pick. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is investors writing for investors.